|
1. Biologie
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
Recommendations by UK's NICE [Genome Web]
|
|
|
|
|
|
Meanwhile,
NICE did not recommend Agendia's MammaPrint for guiding adjuvant
chemotherapy decisions for people with ER-positive, HER2‑negative, and
lymph node-negative early breast cancer, deciding it is not cost
effective. Also, NICE did not recommend IHC4+C for this purpose "because
the analytical validity of the test is uncertain."
|
|
|
|
|
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5. Traitements
|
|
|
Pancreatic cancer [NICE]
|
|
|
|
|
|
This
quality standard covers diagnosis of pancreatic cancer and management
of pancreatic ductal adenocarcinoma in adults aged over 18. This quality
standard describes high-quality care in priority areas for improvement.
It does not cover national initiatives, such as cancer screening or
audit.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
FDA approves pembrolizumab for Merkel cell carcinoma [FDA]
|
|
|
|
|
|
Approval
was based on Cancer Immunotherapy Trials Network protocol 9 (CITN-09),
also known as KEYNOTE-017 (NCT02267603), a multicenter, non-randomized,
open-label trial that enrolled 50 patients with recurrent locally
advanced or metastatic MCC who had not received prior systemic therapy
for their advanced disease.
|
|
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques [ESMO Press Release]
|
|
|
|
|
|
“We
are counting on new technologies that have now matured. Next generation
sequencing has made identification of vaccine targets more efficient,
reliable, and cheaper. The algorithms to interpret this data are
benchmarked and validated for predicting which targets are most likely
to be immunogenic. Sequencing technologies are only going to get better
and prediction tools will become even more accurate.”
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Lenvatinib for untreated advanced hepatocellular carcinoma [NICE]
|
|
|
|
|
|
Lenvatinib
is recommended as an option for untreated, advanced, unresectable
hepatocellular carcinoma in adults, only if: they have Child–Pugh grade A
liver impairment and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1 and the company provides it according to
the commercial arrangement.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.12 Ethique
|
|
|
Top Cancer Doctor Resigns as Editor of Medical Journal [NY Times]
|
|
|
|
|
|
Dr.
José Baselga, the former chief medical officer of Memorial Sloan
Kettering Cancer Center, resigned under pressure on Wednesday as one of
the editors-in-chief of Cancer Discovery, a prominent scientific
journal, after he failed to accurately disclose his conflicts of
interest in dozens of articles in medical journals.
|
|
|
|
|
|
|
6.2 Implants mammaires
|
|
|
|
6.6 Publications
|
|
|
|
|
6.8 Communication
|
|
|